Antibodies

03 Apr 2020 Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
03 Apr 2020 Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
03 Apr 2020 Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
02 Apr 2020 University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
02 Apr 2020 Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
02 Apr 2020 Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
02 Apr 2020 Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
01 Apr 2020 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
01 Apr 2020 InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
01 Apr 2020 Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
01 Apr 2020 Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
01 Apr 2020 EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study
01 Apr 2020 Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination w/ CHP for Adult Patients with Previously Untreated sALCL
31 Mar 2020 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
31 Mar 2020 GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
31 Mar 2020 Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
30 Mar 2020 Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
30 Mar 2020 First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
30 Mar 2020 Imfinzi approved in the US for extensive-stage small cell lung cancer
30 Mar 2020 Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
29 Mar 2020 Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
27 Mar 2020 Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
27 Mar 2020 Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
26 Mar 2020 First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
26 Mar 2020 Eisai submits marketing authorization application in Japan for anticancer agent denileukin diftitox (genetic recombinant) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top